J W ten Cate

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi Evolution of therapies in deep vein thrombosis management
    J W ten Cate
    Faculty of Medicine, University of Amsterdam, The Netherlands
    Blood Coagul Fibrinolysis 10:S5-10. 1999
  2. ncbi Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
    F Turkstra
    Center for Haemostasis, Thrombosis, Artherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, The Netherlands
    Thromb Haemost 81:345-8. 1999
  3. ncbi Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
    P M Kuijer
    Center for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, University of Amsterdam, The Netherlands
    Arch Intern Med 159:457-60. 1999
  4. ncbi Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees
    B Kuipers
    Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Immunol 152:2438-46. 1994
  5. ncbi Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody
    J Jansen
    Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Clin Immunol 15:45-50. 1995
  6. ncbi Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia
    T van der Poll
    Center of Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Center, University of Amsterdam, Netherlands
    J Infect Dis 169:665-7. 1994
  7. ncbi Detection and clinical relevance of human endotoxemia
    A Sturk
    Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands
    Z Med Lab Diagn 31:147-58. 1990
  8. ncbi Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations
    M T Nurmohamed
    Centre for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, Amsterdam, The Netherlands
    Drugs 53:736-51. 1997
  9. ncbi Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet-activating factor and interleukin 6
    T van der Poll
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Scand J Immunol 43:122-5. 1996
  10. ncbi Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes
    A J Horrevoets
    Departments of Biochemistry and Vascular Medicine of the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 93:3418-31. 1999

Collaborators

Detail Information

Publications11

  1. ncbi Evolution of therapies in deep vein thrombosis management
    J W ten Cate
    Faculty of Medicine, University of Amsterdam, The Netherlands
    Blood Coagul Fibrinolysis 10:S5-10. 1999
    ..This review provides a brief overview of DVT prophylaxis and treatment, focusing on the historical developments in the use of heparin, and highlighting the likely direction of future progress...
  2. ncbi Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
    F Turkstra
    Center for Haemostasis, Thrombosis, Artherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, The Netherlands
    Thromb Haemost 81:345-8. 1999
    ..Previous investigations have suggested a lower prevalence of the factor V Leiden mutation in patients with pulmonary embolism, as compared to patients with deep leg vein thrombosis...
  3. ncbi Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
    P M Kuijer
    Center for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, University of Amsterdam, The Netherlands
    Arch Intern Med 159:457-60. 1999
    ....
  4. ncbi Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees
    B Kuipers
    Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Immunol 152:2438-46. 1994
    ..PAF does not seem to be an important intermediate factor in endotoxin-induced neutrophilia or neutrophil degranulation...
  5. ncbi Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody
    J Jansen
    Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Clin Immunol 15:45-50. 1995
    ..Our results indicate that tumor necrosis factor-alpha is a prime mediator of endotoxin-induced release of its own soluble receptors...
  6. ncbi Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia
    T van der Poll
    Center of Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Center, University of Amsterdam, Netherlands
    J Infect Dis 169:665-7. 1994
    ..Neutralization of the early endotoxin-induced TNF activity by anti-TNF caused a marked reduction in IL-1RA concentrations (P < .05). These results indicate that TNF is an intermediate factor in IL-1RA release in endotoxemia...
  7. ncbi Detection and clinical relevance of human endotoxemia
    A Sturk
    Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands
    Z Med Lab Diagn 31:147-58. 1990
    ..94) and level of consensus to establish endotoxemia (93%) as compared to the house method. The commercial assay may therefore facilitate the introduction of endotoxin testing in other laboratories...
  8. ncbi Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations
    M T Nurmohamed
    Centre for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, Amsterdam, The Netherlands
    Drugs 53:736-51. 1997
    ..LMWH compounds have at least a similar efficacy and safety as UFH in haemodialysis. In addition, they simplify the anticoagulant regimen because of the efficacy of a single predialysis bolus injection...
  9. ncbi Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet-activating factor and interleukin 6
    T van der Poll
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Scand J Immunol 43:122-5. 1996
    ..IL-10 release elicited by injection of endotoxin is not mediated by PAF or IL6...
  10. ncbi Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes
    A J Horrevoets
    Departments of Biochemistry and Vascular Medicine of the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 93:3418-31. 1999
    ..These results substantiate the complex change in the gene expression pattern of vascular endothelial cells, which accompanies the inflammatory reaction of atherosclerotic lesions...
  11. ncbi Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes
    C J de Vries
    Departments of Biochemistry and Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    J Biol Chem 275:23939-47. 2000
    ..Moreover, we identified interesting candidate genes that may play a role in the differentiation of SMCs during atherogenesis...